Skip to content
lifestyle.independent.mk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
FibroBiologics, Inc.
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
August 27, 2026
FibroBiologics Regains Compliance with Nasdaq Trading Rules
August 26, 2026
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
August 18, 2026
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
August 11, 2026
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
August 5, 2026
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
July 31, 2026
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 24, 2026
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 24, 2026
1
2
3
Next Page
→